drugset / Trial / NCT01684098

Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor

NCT01684098 ↗

Phase 2 Completed 40 enrolled Endocyte
NaSingle-groupOpen-labelOther

Summary

The folate receptor is over-expressed on many types of cancer cells and new folate receptor targeted therapies are being developed to target cancer cells that over-express the folate receptor. As with other targeted therapies, it is important to develop diagnostic tests that will provide accurate information on folate receptor status and aid in selecting patients that may benefit from folate-targeted therapy.

Timeline

Start
2003-08
Primary completion
—
Completion
2005-08

Drugs

EvaluationDrugModalityDoseRoute
Subject TECHNETIUM (99MTC) ETARFOLATIDE Diagnostic / imaging agent — —